Mainz Biomed (NASDAQ:MYNZ) Now Covered by Analysts at Maxim Group

Maxim Group started coverage on shares of Mainz Biomed (NASDAQ:MYNZ) in a research report report published on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $14.00 price target on the stock.

Separately, HC Wainwright cut shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a report on Monday, November 25th.

Mainz Biomed Trading Down 7.5 %

Shares of MYNZ opened at $6.04 on Friday. Mainz Biomed has a one year low of $3.65 and a one year high of $45.60. The company has a 50-day moving average of $5.32 and a two-hundred day moving average of $9.35.

Institutional Trading of Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC bought a new position in Mainz Biomed (NASDAQ:MYNZ) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned approximately 0.92% of Mainz Biomed as of its most recent SEC filing.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.